University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

2011

The Role of Microvascular Complications in the Relationship
between Glycemic Control and Depressive Symptomatology in
Patients with Type 1 Diabetes: A Mediational Study
Laura Lynn Mayhew
University of South Florida, lmayhew@mail.usf.edu

Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the American Studies Commons, and the Clinical Psychology Commons

Scholar Commons Citation
Mayhew, Laura Lynn, "The Role of Microvascular Complications in the Relationship between Glycemic
Control and Depressive Symptomatology in Patients with Type 1 Diabetes: A Mediational Study" (2011).
Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/3238

This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been
accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons.
For more information, please contact scholarcommons@usf.edu.

The Role of Microvascular Complications in the Relationship between Glycemic Control
and Depressive Symptomatology in Patients with Type 1 Diabetes:
A Mediational Study

by

Laura L. Mayhew

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Arts
Department of Psychology
College of Arts and Sciences
University of South Florida

Major Professor: William P. Sacco, Ph.D.
Paul B. Jacobsen, Ph.D.
Brent J. Small, Ph.D.

Date of Approval:
March 24, 2011

Keywords: A1c, depression, nephropathy, neuropathy, retinopathy
Copyright © 2011, Laura L. Mayhew

Acknowledgments
I would like to thank my advisor, Dr. William Sacco, and thesis committee
members, Dr. Paul Jacobsen and Dr. Brent Small, for their instruction and guidance while
I worked to complete this thesis. I am grateful for the support and invaluable advice of
my labmates, Cathy Bykowski and Kristi White. I would also like to express my
appreciation to my family, friends, and loved ones for their constant support and
encouragement during this process.

Table of Contents
List of Tables .................................................................................................................... iii
List of Figures ................................................................................................................... iv
Abstract ...............................................................................................................................v
Introduction .........................................................................................................................1
Diabetes Mellitus Classification .............................................................................1
Glycemic Control ....................................................................................................2
Diabetes Complications ..........................................................................................3
Retinopathy .................................................................................................4
Neuropathy ..................................................................................................4
Nephropathy ................................................................................................5
Glycemic Control and Diabetes Complications ......................................................5
The Diabetes Control and Complications Trial (DCCT) ............................6
Effect of DCCT A1c reduction on retinopathy ...............................7
Effect of DCCT A1c reduction on nephropathy .............................8
Effect of DCCT A1c reduction on neuropathy ...............................8
UK Prospective Diabetes Study (UKPDS) .................................................9
Depression .............................................................................................................10
Depression and Diabetes .......................................................................................10
Glycemic Control and Depression ........................................................................11
Diabetes Complications and Depressive Symptomatology ..................................13
Current Study ........................................................................................................14
Method ..............................................................................................................................19
Participants ............................................................................................................19
Materials ...............................................................................................................21
Depressive symptomatology .....................................................................21
Neuropathy ................................................................................................22
Retinopathy ...............................................................................................22
Nephropathy ..............................................................................................23
Alc .............................................................................................................24
Procedure ..............................................................................................................24
Statistical Analysis ................................................................................................25
Results ...............................................................................................................................36
Descriptives, t-tests, and Correlational Analyses .................................................36
Single Mediation Model Analyses ........................................................................37
i

Multiple Mediation Model Analyses ....................................................................38
Discussion .........................................................................................................................47
The Relationship Between A1c, Complications, and Depressive
Symptoms .......................................................................................................47
Strengths ...............................................................................................................49
Clinical Implications .............................................................................................51
Limitations ............................................................................................................52
Future Directions ..................................................................................................53
Conclusion ............................................................................................................53
References .........................................................................................................................55
Appendix A: Symptom Checklist-90-Revised Depression Dimension Subscale ..............64
Appendix B: Neuropathy Measurement Definition ..........................................................66

ii

List of Tables
Table 1.

Participant Baseline Descriptive Characteristics and Demographic
Information .....................................................................................................29

Table 2.

Diabetes Control and Complications Trial Neurologic End Point
Definitions .......................................................................................................30

Table 3.

Abbreviated Summary of the Final Version of the Early Treatment
Diabetic Retinopathy Study Scale of Diabetic Retinopathy Severity for
Individual Eyes ...............................................................................................31

Table 4.

Abbreviated Final Version of the Early Treatment Diabetic
Retinopathy Study Scale of Diabetic Retinopathy Severity for Persons ........32

Table 5.

Diabetes Control and Complications Trial Scale of Nephropathy ..................33

Table 6.

Descriptive Statistics and Correlations of Average A1c, Retinopathy,
Nephropathy, Neuropathy, and Depressive Symptomatology Levels ............41

Table 7.

Mediation of the Effect of DCCT Treatment Group on Microvascular
Complications through A1c for the full DCCT Group, and the Primary
and Secondary Intervention Cohorts ...............................................................42

Table 8.

Mediation of the effect of A1c on depressive symptomatology through
the microvascular complications of retinopathy, nephropathy, and
neuropathy in the full DCCT participant cohort, primary prevention
cohort, and secondary intervention cohort ......................................................43

iii

List of Figures
Figure 1. Graphical representation of the hypothesized simple-mediator model
of DCCT intervention treatment condition, A1c, and microvascular
diabetes complications ....................................................................................34
Figure 2. Graphical representation of the hypothesized multiple-mediator model
of A1c, microvascular diabetes complications, and depressive
symptomatology ..............................................................................................35
Figure 3. Multiple mediation test of the role of microvascular complications in
the relationship between A1c and depressive symptomatology for the
full DCCT sample ...........................................................................................44
Figure 4. Multiple mediation test of the role of microvascular complications in
the relationship between A1c and depressive symptomatology for the
primary prevention cohort of the DCCT .........................................................45
Figure 5. Multiple mediation test of the role of microvascular complications in
the relationship between A1c and depressive symptomatology for the
secondary intervention cohort of the DCCT ...................................................46

iv

Abstract
People with diabetes are at double the risk of developing depression. Depression
is associated with increased morbidity and mortality in people with diabetes.
Levels of A1c have been linked to microvascular complications (e.g., retinopathy,
nephropathy, and neuropathy) as well as depression. The interrelationship
between A1c, microvascular complications, and depression has not previously
been investigated in a comprehensive model, and a better understanding of the
nature of these associations is needed. Preliminary analyses test the assumption
that A1c mediates the relationship between group assignment in the Diabetes
Control and Complications Trial (DCCT) and microvascular complications. The
primary purpose of the study is to examine multiple mediation models, which
hypothesize that the severity of microvascular complications mediates the
relationship between A1c and depressive symptomatology levels. Participants
were people with type 1 diabetes (N = 1441) enrolled in the DCCT, a longitudinal
randomized controlled trial investigating intensive insulin treatment and diabetes
complications, and divided into primary (e.g., no retinopathy) and secondary (e.g.,
mild retinopathy) cohorts. Biological markers were used to measure A1c and
microvascular complications. Depressive symptomatology was measured by the
depression subscale of the Symptom Checklist-90-Revised. Simple and multiple
mediation analyses were used to test proposed models. A1c mediates the
relationship between DCCT group assignment and microvascular complications.
v

Microvascular complications partially mediate the relationship between A1c and
depression for the full sample and secondary cohort. Results support the
hypothesis that the severity of microvascular complications, in part, accounts for
the association between A1c and depressive symptomatology in people with type
1 diabetes.
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Introduction
Diabetes mellitus is an endocrinological and metabolic disease that involves the
dysregulation of the use and/or the production of insulin, the hormone that is required for
regulation of glucose in the body. Hyperglycemia, or elevated blood glucose levels, is the
hallmark characterization of the disease (The Expert Committee on the & Classification
of Diabetes Mellitus, 2003). Diabetes is a chronic disorder that affects some 24 million
people in the United States, or nearly 8% of the population. It is the seventh leading
causes of death in the country, and the disease doubles the risk of death for its sufferers
compared to their same-aged non-diabetic counterparts (Centers for Disease Control and
Prevention, 2008).
Diabetes Mellitus Classification
The overwhelming majority of diabetes cases fall into two main, etiologically
distinct categories: type 1, accounting for about 5 to 10% of all diabetes cases, and type
2, accounting for about 90 to 95% of diabetes cases (Centers for Disease Control and
Prevention, 2008). Type 1 diabetes, formerly known as juvenile or insulin-dependent
diabetes, commonly occurs in childhood and adolescence and is considered an
autoimmune disease in which beta cells of the pancreas are destroyed by the immune
system. The destruction of beta cells typically leads to a complete deficiency in insulin
and treatment with an exogenous supplementation of insulin is essential for survival in
most cases (The Expert Committee on the & Classification of Diabetes Mellitus, 2003).
Patients with type 1 diabetes must carefully monitor their blood glucose levels and inject
1

themselves with insulin to regulate glucose levels multiple times throughout each day to
manage the disease (Executive Summary: Standards of Medical Care in Diabetes, 2009;
Van Tilburg, et al., 2001).
Type 2 diabetes, formerly known as non-insulin dependent or adult-onset
diabetes, is characterized by a resistance to the action of insulin, a relative deficiency of
insulin production, or both. Insulin resistance leads to deficiency in the necessary insulin
action required for the proper metabolism of carbohydrates, fats, and proteins (The
Expert Committee on the & Classification of Diabetes Mellitus, 2003). Relative insulin
deficiency means that insulin may still be produced, but the pancreas does not produce a
sufficient amount of insulin needed to meet the needs of the body (Van Tilburg, et al.,
2001). Autoimmune destruction of pancreatic beta cells does not occur in type 2 diabetes,
as is central to type 1 diabetes, and lifestyle factors are often associated with the
development of type 2 diabetes (The Expert Committee on the & Classification of
Diabetes Mellitus, 2003). Although some patients with type 2 diabetes require insulin
supplementation to treat their diabetes, treatment with oral medications and lifestyle
modifications, including changes in diet and exercise, are often sufficient for the
management of type 2 diabetes (Centers for Disease Control and Prevention, 2008; Van
Tilburg, et al., 2001).
Glycemic Control
Regardless of the type of diabetes, the main goal for treatment is to reach and
maintain a healthy range of blood glucose levels, often referred to as glycemic control.
Hemoglobin A1c (A1c) is a weighted measure of the average blood glucose level over
the past 60 to 90 days, with more weight given to the previous 30 days in the calculation
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(Lustman, Griffith, Freedland, & Clouse, 1997). A1c shows the degree of glucose
exposure over time and is often used to measure how well diabetes is being managed
over several months (Nathan, Kuenen, Borg, Zheng, Schoenfeld, & Heine, 2008).
Patients with diabetes, especially type 1, routinely test their blood glucose levels, and
according to Nathan et al. (2008), there is a direct, consistent, and linear relationship
between mean glucose and A1c. Therefore, A1c is a good measure of how well glucose
levels are being managed over time on a day-to-day basis. Guidelines for optimum
management of diabetes suggest that blood glucose levels remain as low as possible
without risk of hypoglycemia or a hemoglobin A1c level of 7% or less (Qaseem, et al.,
2007). Alc is such an informative value for people with diabetes that not only do
practitioners set treatment goals by this number, it has recently become part of the
diagnostic criteria for diabetes (Executive Summary: Standards of Medical Care in
Diabetes, 2010). A1c is a better marker for the presence and severity of diabetes than
single measure of glucose concentration and current standards state that diabetes should
be diagnosed when an A1c value at or above 6.5% is present and a repeat of A1c testing
elicits a similar value to confirm the diagnosis (The International Expert).
Diabetes Complications
Microvascular complications of diabetes, including retinopathy, neuropathy, and
nephropathy, are caused by damage to and disease of the microvasculature portion, or
small blood vessels, of the body. Because these diabetes-related complications can
severely negatively impact quality of life and increase mortality rates, prevention, early
detection, reduction, and treatment of these complications is of utmost importance for
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people with diabetes and their healthcare providers. Adequate control of glycemic levels
is essential for the prevention and control of these often devastating complications.
Retinopathy. Diabetic retinopathy, a term used to describe damage in the blood
vessels of the eye, is the most common diabetic eye disease and one of the leading causes
of blindness in adults in the United States. There are four stages of diabetic retinopathy
ranging from mild, moderate, and severe nonproliferative retinopathy, to the most severe
stage of proliferative retinopathy. Microaneyurisms in the blood vessels of the retina,
blockage of some blood vessels that feed the retina, and advanced blockage of retinal
blood vessels causing deprivation of blood to the retina are characteristic of mild,
moderate, and severe nonproliferative retinopathy, respectively. Proliferative retinopathy
occurs when blockage of retinal blood vessels is so severe the growth of new abnormal
and fragile blood vessels is triggered which can easily break causing visual damage and
even blindness (National Eye Institute, 2009). The majority of people with diabetes will
experience some degree of retinopathy during the course of the disease, however there is
variability in stage and severity of the retinopathy and it is in part dependent upon the
duration of diabetes (Nathan, 1993).
Neuropathy. Diabetic neuropathies are nerve disorders caused by diabetes that
involve damage to nerves throughout the body. Symptoms vary by type of neuropathy
and by the nerve type affected and some neuropathies may be asymptomatic. Typically,
symptoms start with tingling, numbness, or pain in the feet and can increase to
gastrointestinal disturbance, sexual dysfunction, weakness, dizziness, and foot and hand
muscle atrophy. Different categories of neuropathy exist including peripheral, autonomic,
proximal, and focal. Peripheral is the most common type of neuropathy in people with
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diabetes and causes pain or numbness in the extremities (i.e., toes, feet, legs, hands, and
arms). Autonomic neuropathy affects nerves that control the heart, blood pressure, lungs
and eyes and can cause bladder, gastrointestinal, and sexual dysfunction and may
preclude the signs of hypoglycemia from occurring. Proximal neuropathy may lead to
pain and weakness in the leg and buttocks area, and focal neuropathy is characterized by
sudden pain or weakness of the muscle and can affect any nerve throughout the body
(National Diabetes Information Clearinghouse, 2009).
Nephropathy. Diabetic nephropathy is damage to or disease of the kidneys that is
thought to develop as a complication from a combination of elevated blood sugar levels
and hypertension. Excessive blood sugar may damage and destroy nephrons, the units of
the kidney that filter waste from the body. Eventually, as more nephrons are destroyed
albumin protein may leak from the kidney and into the urine. Nephropathy is a
progressive disease that is the leading cause of long-term kidney failure and end-stage
kidney disease in the United States and a major cause of illness and even death in people
with diabetes. Patients with nephropathy often require dialysis or kidney transplantation
(American Diabetes Association 2004).
Glycemic Control and Diabetes Complications
A1c is considered a value of central concern in the diagnosis and evaluation of
management in diabetes largely because of a strongly established link between glycemic
control and long-term diabetes complications. This connection is the basis for the
recommendation of maintaining an A1c value below 7.0% and regular monitoring of A1c
levels. A myriad of previous studies have linked poorly controlled A1c levels to
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numerous microvascular diabetes complications including diabetic peripheral neuropathy,
retinopathy, and nephropathy, among other types of complications.
The Diabetes Control and Complications Trial (DCCT). The Diabetes Control
and Complications Trial (DCCT) was a multicenter randomized longitudinal controlled
clinical trial designed to investigate the influence of intensive exogenous insulin
treatment for people with type 1 diabetes on the development and progression of longterm diabetes complications. The study was designed to examine the effects of standard
versus intensive insulin treatment on the development, progression, and/or resolution of
early vascular complications in patients with type 1 diabetes. Two groups of participants
were enrolled and randomized to either the intensive or standard treatment groups. The
primary intervention group included participants with no background retinopathy and the
secondary intervention group included participants with minimal or low levels of
background retinopathy. Development of microvascular complications was investigated
in the primary prevention group, whereas the progression and resolution of vascular
complications was investigated in the secondary prevention group. The goal for the
experimental group was to maintain blood glucose levels as close to the normal
nondiabetic range as safely possible, with a target A1c level of less than 6.5%. This was
achieved with a minimum of three daily insulin injections or use of an insulin pump for
participants in the intensive treatment group. In contrast, standard care group participants
had only one to two insulin injections daily (DCCT Research Group, 1993a; DCCT
Research Group, 1993b). A more detailed description of the study is presented below in
the procedures section.
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The DCCT was carried out over more than a 10-year period, with continuous
enrollment over a 6 year period, and provided definitive evidence demonstrating the role
of glucose control in the onset, development, and progression of diabetes related
complications. Intensive insulin treatment lead to significant reductions in glycemic
levels for patients with type 1 diabetes and the lowest A1c level for the intensive
treatment group was reached at 6 months into the study (DCCT Research Group, 1993a).
A1c levels were significantly lower in the intensive treatment group relative to
conventional treatment groups after baseline and until the end of the study. Intensive
insulin treatment lead to significant reductions in glycemic levels for patients with type 1
diabetes and the lowest A1c level for the intensive treatment group was reached at 6
months into the study (DCCT Research Group, 1993a).
Effect of DCCT A1c reduction on retinopathy. Results of the DCCT showed that
intensive insulin therapy initially led to transient worsening of retinopathy, especially in
the secondary-intervention cohort during the initiation of therapy. However, these
abnormalities tended to disappear after about 18 months of treatment. Risk of progression
of retinopathy was reduced for patients with early worsening who received intensive
therapy as compared to those in the standard treatment group (DCCT Research Group,
1993a; DCCT Research Group, 1995c; DCCT Research Group, 1995d). Cumulative
retinopathy incidence was not significantly different between the two treatment groups
until about 3 years of treatment for both the primary and secondary-prevention cohorts.
At the 5 year point and onward the cumulative incidence of retinopathy was about 50%
lower for the intensive therapy group than the conventional therapy group in the primaryprevention cohort. Intensive therapy reduced the average adjusted risk of retinopathy by
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76% and risk reduction increased over time in the primary-prevention cohort. In the
secondary-prevention cohort, intensive therapy reduced the average risk of retinopathy
progression by 54% over the duration of the study (DCCT Research Group, 1993a;
DCCT Research Group, 1995c; DCCT Research Group, 1995d).
Effect of DCCT A1c reduction on nephropathy. Diabetic nephropathy is initially
manifested as microalbuminuria, or an increase in urinary albumin excretion. It then
progresses to overt albuminuria followed by renal failure (Krolewski, Laffel, Krolewski,
Quinn, & Warram, 1995). In patients with type 1 diabetes, the risk of microalbuminuria is
strongly related to the degree of hyperglycemia and the risk grows significantly higher
with A1c levels above 10% (Krolewski et al., 1995). Intensive therapy in the DCCT
resulted in lower rates of microalbuminiuria and albuminuria in both cohorts as compared
to the conventional therapy group. The risk of microalbuminuria was reduced by 34%
and 43% for the primary-prevention and secondary-intervention cohorts in the intensive
treatment group, respectively. For the combined cohort, the risk of albuminuria and
microalbuminuria was reduced by 54% and 39% percent, respectively, with the use of
intensive insulin therapy (DCCT Research Group, 1993a; DCCT Research Group,
1995b).
Effect of DCCT A1c reduction on neuropathy. The appearance of clinical
neuropathy, defined by either abnormal autonomic-nerve testing or abnormal nerve
conduction in two or more peripheral nerves plus abnormal neurologic examination, was
reduced by intensive insulin therapy by 69% and 57% for the primary-prevention and
secondary-intervention cohorts without baseline neuropathy, respectively, as compared to
their conventional treatment counterparts. Similar reductions in the individual
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components used to evaluate the presence of clinical neuropathy were also seen with
intensive therapy (DCCT Research Group, 1993a; DCCT Research Group, 1995a). Even
after discontinuation of the DCCT, an eight-year follow up of DCCT participants in the
observational Epidemiology of Diabetes Interventions and Complications (EDIC) showed
a continued higher rate of incidence of signs, symptoms, and clinically diagnosed
neuropathy in participants formerly in the conventional treatment group compared to
those receiving intensive treatment. The higher incidence rates occurred despite the
narrowing and eventual disappearance of glycemic differences between the two groups
(Martin et al., 2006).
UK Prospective Diabetes Study (UKPDS). Similar findings were reported by
the UK prospective diabetes study (UKPDS). The UKPDS was a clinical trial that
examined the effect of intensive blood glucose control in over 4000 people with type 2
diabetes. The relationship between glycemic exposure and diabetes related complications
were similar to those in the DCCT and EDIC. In the prospective study of people with
type 2 diabetes, each 1% reduction in A1c was associated with a 21% reduction in risk of
any diabetes related end point, including microvascular complications, macrovascular
complications, and death. Specifically, a 37% decrease in risk for microvascular
complications occurred with each 1% decrease in A1c level, providing further support of
the relationship between glycemic exposure and diabetes related complications (Stratton
et al., 2000). In summary, research consistently shows a strong predictive association of
elevated glycemic control levels and greater incidence and severity of diabetes related
complications (Diabetes Control and Complications Trial Research Group, 1993; Gaster
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& Hirsch, 1998; Klein, Klein, & Moss, 1996; Klein, Klein, Moss, Davis, & DeMets,
1988; Stratton, et al., 2000)
Depression
Depression can refer to a transient mood state, a constellation of symptoms, and
two clinical diagnoses with strict diagnostic criteria (major and minor depression).
Studies in this area typically examine the extent of depressive symptoms or the presence
or absence of a clinical diagnosis (major depression or minor depression). Major and
minor depression are classified psychological mood disorders, with major depressive
disorder affecting approximately 7% of the general population in a given year (Kessler,
Chiu, Demler, & Walters, 2005). The central characterization of depression is either a
depressed mood or loss of interest or pleasure over a 2-week period. Other symptoms
include fluctuations in weight and/or appetite, fluctuations in sleep patterns, psychomotor
agitation or retardation, fatigue, feelings of worthlessness or excessive guilt,
concentration difficulties, and suicidal ideation, plans, or attempts.
Depression and Diabetes
Depression rates have been estimated to be upwards of twice as high in the
diabetic population than in the general population. In their 2001 meta-analytic study of
the prevalence of comorbid depression in adults with diabetes Anderson and colleagues
analyzed over 40 studies and found the odds of depression in participants with diabetes
were twice that of their non-diabetic control counterparts (Anderson, Freedland, Clouse,
& Lustman, 2001). This doubled odds ratio of the prevalence of depression in the diabetic
population compared to the non-diabetic population was independent of sex, diabetes
type, subject source, or assessment method.
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The co-occurrence of depression and diabetes is significant because previous
research suggests that the comorbidity is associated with a host of problems including
poorer medical regimen adherence, increased functional impairment (Ciechanowski,
Katon, & Russo, 2000), greater symptom burden (Ludman, et al.), higher health care
costs (Egede, Zheng, & Simpson, 2002), and increased mortality rates (W. Katon, et al.,
2008; W. J. Katon, et al., 2005). One study by Katon and colleagues (2008) found a 36%
to 38% increased risk for all-cause mortality for diabetic patients with comorbid
depression compared to their non-depressed diabetic counterparts. A separate study by
Katon and colleagues (2005) suggests that both major and minor depression increase
mortality rates for diabetics with comorbid depression compared to nondepressed
diabetics by nearly two-fold.
Glycemic Control and Depression
As noted earlier, Hemoglobin A1c (A1c), a weighted measure of the average
blood glucose level over the past 60 to 90 days is typically used to measure how well
diabetes is being managed over several months (Lustman, Griffith, Freedland, & Clouse,
1997; Nathan et al., 2008). The American Diabetes Association recommends a treatment
goal of A1c <7% (2009), which would be indicative of good glycemic control. Higher
values of A1c would be indicative of poor glycemic control (American Diabetes
Association 2009).
A1c levels have been linked to depression levels in numerous studies. In their
2000 meta-analytic review of the relationship between depression and glycemic control,
Lustman and colleagues (Lustman, Anderson, Freedland, de Groot, Carney, & Clouse,
2000) analyzed 24 cross-sectional studies with a total of 2,817 participants with both type
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1 and type 2 diabetes. The authors found a significant positive relationship between
depression and A1c, with a small-to-moderate overall effect size. While this study
provides further confirmation for the existence of a relationship between depression and
hyperglycemia, the cross-sectional nature of the data precludes the ability to determine
either directionality of this relationship, or mechanisms explaining the relationship
between the two.
Opposing theories have been proposed regarding the nature of the relationship
between depression, glycemic control, and related physical complications. These
competing theories suggest that depression can be either an antecedent to or a
consequence of symptoms and medical complications related to glycemic control. The
antecedent model suggests that depression adversely influences behavioral (e.g., diabetes
self-care) and physiological mechanisms (e.g., activation of the HPA axis) that result in
poorer glycemic control and, subsequently, a greater incidence and severity of diabetes
complications. (William P. Sacco & Bykowski, 2010). An alternative theory suggests
that depression is a consequence of poor adherence and/or diabetes medical symptoms
resulting from poor glycemic control. The consequence model suggest that failure to
effectively adhere to the complicated diabetes self-management regimen leads to negative
self-relevant cognitions (e.g., low self-efficacy), poorer glycemic control, and increased
incidence and severity of medical complications. Depression results from these
experiences. For example, Sacco, Wells, Friedman, Matthew, Perez, and Vaughan
(2007) found that body mass index (BMI; an indicant of adherence in people with type 2
diabetes) was associated with diabetes medical symptoms and depression in people with
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type 2 diabetes. Diabetes symptoms mediated the relationship between BMI and
depression, providing support for the consequence model.
Similarly, Sacco and Bykowski (2010) found that A1c was associated with
depression levels in people with type 1 diabetes, and participants’ thoughts about their
ability to effectively manage their disease (diabetes self-efficacy) mediated this
relationship. This finding is consistent with the proposal that depression occurring in
people with type 1 diabetes may be a consequence of negative cognitive appraisals
resulting from their ability to keep their A1c levels at healthy levels.
Diabetes Complications and Depressive Symptomatology
Diabetes complications have been linked to increased levels of depression and
depressive symptomatolgy within the diabetic population. In their 2001 meta-analytic
study of the association of depression and diabetes complications de Groot and
colleagues attempted to evaluate the strength and consistency of this relationship (de
Groot, Anderson, Freedland, Clouse, & Lustman, 2001). Additionally, they sought to
determine if the relationship between diabetes complications and depressive symptoms
differed by diabetes type. The authors examined a total of 27 studies that evaluated the
relationship between depression and at least one complication of diabetes including
diabetic retinopathy, diabetic neuropathy, diabetic nephropathy or end stage renal
disease, macrovascular complications, and sexual dysfunction.
Overall, the authors found a moderate effect size for the relationship between
depression and all diabetes complications. Moderate effect sizes were found for the
relationship between depression and all individual diabetes complications (i.e.,
nephropathy, neuropathy, sexual dysfunction, and macrovascular disease alone) apart
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from retinopathy for which a small to moderate effect size was found. Overall, higher
depression levels were associated with higher numbers and greater severity of diabetes
related complications. Additional analyses indicated that greater numbers of
complications were associated with higher depression levels. Further, moderator analyses
by diabetes type (i.e., type 1 and type 2) indicated similar moderate effect sizes for both
types. The similar effect size for the relationship between depression and diabetes
complications in patients with type 1 and type 2 diabetes suggests that common pathways
may exist to explain this association despite the disparate physiological manifestations
and distinctions of these diseases. Despite the consistent relationship found between
depression levels and the presence and severity of diabetes complications, all of the
studies included in the meta analysis are cross sectional (de Groot et al., 2001).
Therefore, the temporal relationship between depression and diabetes complications is
not elucidated through these findings .
Current Study
Meta-analytic methods have provided evidence that people with diabetes are at a
two-fold increased risk of depression relative to their non-diabetic counterparts
(Anderson et al., 2001). Myriad studies, including large-sample, longitudinal, and
experimental studies (DCCT Research Group, 1993a) have demonstrated a consistent
relationship between glycemic control and diabetes-related microvascular complications.
Poor glycemic control, as measured by elevated A1c levels, is consistently linked to
greater occurrence and severity of diabetic complications including retinopathy,
neuropathy, and nephropathy. Meta-analyses also show a consistent relationship between
glycemic control and depression (Lustman et al., 2000), with poorer glycemic control
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associated with increased levels of depression and depressive symptomatology. Metaanalytic techniques also demonstrate a consistent relationship between diabetes related
complications and depression, with a positive relationship between the number and
severity of diabetes related complications and levels of depression and depressive
symptomatology (de Groot et al., 2001).
Previous research has demonstrated a positive relationship between A1c and
diabetes complications, A1c and depression, and diabetes complications and depression.
However, the mechanisms explaining the glycemic control and depression connection
have not yet been elucidated. Additionally, although the available literature shows
consistency with the relationships between glycemic control, diabetes complications, and
depression levels, several limitations exist. Most studies address the relationship between
two of these variables but do not provide a model examining the relationship between all
three, leaving the interrelationship between A1c, microvascular diabetes complications,
and depressive symptomatology unclear. Furthermore, competing theories exist regarding
the nature of the relationship between diabetes related health complications and
depression. The antecedent model suggests that depression may contribute to
physiological and behavioral changes that negatively influence glycemic control and,
therefore, symptoms and complications. The consequence model suggests that depression
occurs consequentially to increased medical symptoms and complications that arise from
poor glycemic control (Sacco et al., 2007; Sacco & Bykowski, 2010). Further studies
within these theoretical frameworks are needed to elucidate the nature of the relationship
between these variables. Furthermore, current literature is largely based on crosssectional data precluding the ability to elucidate the temporal relationship between these
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variables. With the exception of longitudinal experimental studies showing that better
glycemic control can delay the onset and reduce the severity of diabetes complications
(DCCT Research Group, 1993a), the cross-sectional nature of much of the research in
this area does not allow for conclusions about the temporal nature of the relationships to
be drawn.
The current study seeks to address the limitations of previous research by
analyzing the relationship between A1c, microvascular diabetes complications, and
depressive symptomatology in meditational models using longitudinal experimental data
based on an a priori theoretical framework. The role of diabetes related complications as
a mechanism explaining the relationship between A1c and depressive symptomatology
were explored in the current study within the depression-as-consequence model.
First, preliminary analyses of the effect of DCCT group assignment (intensive
treatment versus control) on the presence and severity of microvascular complications
were evaluated in three separate models (analyzing each microvascular complication
independently), evaluating A1c as a mediator of the treatment effect. These analyses were
intended to test the assumption that A1c is the mechanistic variable explaining the
relationship between DCCT group assignment and lower incidence and severity of
diabetes related complications and provide evidence for the nature of the relationship
between DCCT treatment group, A1c, and microvascular complications. These models
will also help to establish a foundation for further analysis of the relationship between
A1c, microvascular complications, and depression. The depression-as-consequence
model was then evaluated in a separate multiple-mediator model with A1c predicting
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later depressive symptomatology, and microvascular complications examined as
mediators of the relationship between A1c and depression.
Four main hypotheses were proposed to test preliminary analyses of the
relationship between DCCT treatment condition, A1c, and diabetes related microvascular
complications, as depicted graphically in Figure 1. First, treatment group was expected to
affect the incidence and severity of diabetes complications, with decreased incidence and
severity of each complication found in the intensive treatment group. Second, intensive
treatment condition was expected to result in lower A1c values. Third, A1c was expected
to be positively related to the incidence and severity of the microvascular diabetes related
complications of retinopathy, nephropathy, and neuropathy. Fourth, it was predicted that
the effect of treatment condition on the incidence and severity of microvascular
complications will be fully mediated by A1c. These hypotheses were tested through three
simple-mediation models for each microvascular diabetes related complication.
Four main hypotheses were proposed for the relationship between A1c,
microvascular diabetes related complications, and depressive symptomatology, as
depicted graphically in Figure 2. First, it was expected that A1c will be positively
associated with levels of depressive symptomatology. Secondly, A1c was expected to be
positively related to the presence and severity of diabetes related microvascular
complications of retinopathy, neuropathy, and nephropathy. Third, microvascular
diabetes complications were expected to be positively related to depressive
symptomatology. Lastly, it was predicted that the presence and severity of microvascular
diabetes related complications will fully mediate the relationship between A1c and
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depressive symptomatology. These hypotheses were tested in a single multiple-mediator
analysis.
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Method
This study utilized data from the Diabetes Complications and Control Trial
(DCCT). The DCCT was a 29 center, randomized clinical trial that compared the effects
of intensive diabetes therapy to standard treatment on the development and progression of
complications among individuals with type 1 diabetes. The study was designed to
examine the effects of standard versus intensive treatment on the development,
progression, and/or resolution of early vascular complications in patients with type 1
diabetes. Participants were categorized as either primary or secondary prevention group
participants based on the absence or presence of minimal diabetic retinopathy,
respectively, at study initiation (DCCT Research Group, 1986). The study, funded by the
National Institute of Diabetes and Digestive and Kidney Diseases, was initiated in 1983
and ended in 1993.
Participants
Participants included 1441 generally healthy people with type 1 diabetes who
ranged from 13 to 39 years of age at the time of randomization. Of the 1441 participants,
726 who had no diabetic retinopathy were considered primary prevention participants,
and 715 who had minimal background diabetic retinopathy at the start of the study were
considered secondary prevention subjects. For the primary prevention group participants,
eligibility requirements included type 1 diabetes duration for at least one year but no
more than five years, absence of diabetic retinopathy, visual acuity of at least 50 letters in
both eyes, and less than 40 mg albumin per 24 hours on a four-hour standardized urine
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collection. Eligibility criteria for secondary prevention subjects included type 1 diabetes
duration of at least one year but no more than 15 years, presence of at least one
microaneurysm in either eye but less retinopathy than would characterize either eye as P2
or worse based on central grading of stereo fundus photographs, visual acuity of at least
45 letters in both eyes, and 200 mg or less albumin per 24 hour on a four-hour
standardized urine collection (DCCT Research Group, 1993b). See Table 1 for full
demographic information and baseline descriptive values for the full sample, and primary
prevention and secondary intervention cohorts.
Exclusion criteria for the study participants were: previous intensive insulin
treatment; C-peptide levels greater than .2 or .5 pmol/ml for participants with type 1
diabetes duration greater than 5 years or less than 5 years, respectively; insulin resistance;
three or more episodes of diabetic ketoacidosis requiring hospitalization in the year
before randomization; pregnancy or plans for pregnancy within 2 years of randomization;
hypertension; hyperlipidemia; urinary tract infection;, history of drug or alcohol abuse
during the five years prior to randomization; diabetic neuropathy, hypothyroidism;
obesity as defined as a body weight greater than 130% of ideal body weight; chronic
disease requiring medication for greater than 4 months during the year before
randomization; history of coronary heart disease or symptomatic peripheral vascular
disease; history of epilepsy or seizures requiring medication; presence of serious mental
disorders that would interfere with protocol adherence; among other criteria (DCCT
Research Group, 1993b).
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Materials
Depressive symptomatology. The Symptom Checklist 90-Revised (SCL-90-R;
Derogatis, 1994) was used to measure depressive symptomatology. The SCL-90-R is a
90-item self-report symptom inventory and is a widely used measure of current
psychiatric symptoms. It is designed to screen a broad range of psychological problems in
nine primary symptom dimensions, including: Somatization, Obsessive-Compulsive,
Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid
ideation, and Psychoticism. Additionally, overall psychological distress is measured by
the Global Severity Index, the Positive Symptom Total, and the Positive Symptom
Distress Index. Each item is rated on a five-point Likert-type scale of overall distress
level with scores ranging from 0 (“not at all”) to 4 (“extremely”).
The 13 item depression subscale of the SCL-90-R was used to assess the extent to
which participants experienced depressive symptoms during the past 7 days. A range of
depressive symptoms were assessed, including dysphoric mood, anhedonia, loss of
energy, feelings of hopelessness, and thoughts of suicide. Participants rated the severity
of their depressive symptomatology experiences over the past week on a 5-point scale
ranging from 0 (“not at all”) to 4 (“extremely”). Total subscale scores are calculated by a
summation of the item responses, and raw scores can be derived by dividing the total
score by the number of items on the scale (i.e., 13 for the depression subscale). High
internal consistency (α = .90) has been reported for the depression subscale of the SCL90-R (Derogatis, 1994; Derogatis & Savitz, 1999) .Adequate to good test-retest reliability
has been established with 1-week (r = .82) and 10-week (r = .75) intervals between
testing (Derogatis; Derogatis & Savitz). The validity of the depression subscale of the
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SCL-90-R has been demonstrated through high correlations with other measures of
depressive symptomatology, including the Beck Depression Inventory (Peveler &
Fairburn, 1990). The full SCL-90-R depression subscale can be seen in Appendix A.
Neuropathy. Clinical and electrodiagnostic criteria were used to determine the
presence of neuropathy. Neurological evaluations were performed by neurologists
blinded to treatment group assignment. Any non-diabetic causes of neuropathy were
identified. Table 2 provides detailed diagnostic criteria and diagnostic categories (DCCT
Research Group, 1995a). Further details are provided in Appendix B.
A 3-point rating scale was used to determine participant neuropathy level.
Participants were classified as either having definite neuropathy (1), possible neuropathy
(2), or no neuropathy (3). Definite neuropathy was confirmed by the presence of at least
two of the following: physical symptoms, abnormalities on the sensory examination,
and/or absence or decrease in deep-tendon reflexes. Participants with only one abnormal
finding among physical and sensory symptoms and deep-tendon reflexes, with or without
abnormal nerve conduction, were classified as having possible clinical neuropathy. All
other participants were classified as having no neuropathy present (Albers, et al., 2007).
Retinopathy. Retinopathy was measured by an assessment of the grading of
severity of lesions of diabetic retinopathy for each eye every six months. Lesion grades
were used to determine overall severity of retinopathy according to Early Treatment
Diabetic Retinopathy Study (ETDRS) interim and final scales. Seven-field stereoscopic
color fundus photographs were independently graded by two graders masked to treatment
for rating reliability. Grades that differed by two or more steps were assessed by a senior
grader who assigned a final grade and a single grading was completed for photographs
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from nonannual follow-up visits. Additionally, sets of photographs were periodically
regraded to ensure reproducibility of the grading system. Agreement comparisons were
complete in 53.3% to 67.6% of cases, within one step 84.3% to 95.0% of cases, and
within two steps 96.2% to 98.3% of comparison cases (DCCT Research Group, 1995b).
Retinopathy severity ratings ranged from a scaled score of 10 to a scaled score of 85,
indicative of the absence of diabetic retinopathy to advanced proliferative diabetic
retinopathy or partially obscured fundus, respectively. A 10-point scale ranging from 1 to
10 was used to indicate retinopathy severity based on scaled score ratings. Severity
ratings included no retinopathy, very mild, mild, moderate, and severe nonproliferative
diabetic retinopathy, and mild, moderate, high-risk, and advanced proliferative diabetic
retinopathy (DCCT Research Group, 1995d). Definitions of the ETDRS severity levels of
retinopathy for can be seen in Table 3. The ratings of retinopathy levels for each
individual eye as based on the ETDRS severity level (Table 3) were used to determine
overall retinopathy severity level for the person (Table 4). Change over time in
retinopathy severity was a primary outcome of the DCCT. Sustained progression of
retinopathy was considered present with a cumulative increase by three or more steps on
the scale at two consecutive visits, shown in Table 4.
Nephropathy. Nephropathy level was measured at annual follow-up visits
through urine collection over a four-hour collection time period. Urine samples were
obtained after participants had breakfast and their morning insulin dose and while they
were resting and in a sitting position. Participants were asked to avoid caffeinated
beverages the day of and strenuous exercise during the day prior to testing. The level of
nephropathy was determined by measurement of Albumin Excretion Rate (AER) in units
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of mg/24 hours and standard Creatinine Clearance in units of ml/min. Participants were
categorized into a six-point nephropathy level scale based upon AER and Creatinine
Clearance levels. An AER less than 40mg/24 hours is indicative of level 1 nephropathy,
and an AER greater than 300 mg/24 hours and a Creatinine Clearance level below 70
ml/min was indicative of level 6 nephropathy (See Table 5; DCCT Research Group,
1995b).
A1c. Glycosylated hemoglobin (A1c) was measured at baseline, at quarterly
visits, and at study closeout for participants in the standard treatment condition.
Participants in the intensive treatment group had A1c measured at baseline, monthly
visits, and study closeout. Blood samples for A1c were assayed in the Central
Biochemistry Laboratory.
Procedure
Participants were randomized to either standard or intensive diabetes therapy and
followed for an average of 6.5 years (DCCT Research Group, 1993a; DCCT Research
Group, 1993b). Patients assigned to the standard diabetes management group had one to
two daily insulin injections with daily self-monitoring. Additionally, patients in the
standard therapy group received an individualized meal plan with dietitian reinforcement
every six months, an education program, and standard clinic visits and monitoring at
three month intervals (DCCT Research Group, 1993b). Patients in the intensive treatment
group received a minimum of three daily insulin injections or used an insulin pump with
self-monitoring of blood glucose a minimum of four times daily. They received the same
dietary management principles as the standard therapy group with reinforcement from the
dietitian as often as necessary to attain treatment goals. Additionally, patients in the
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intensive treatment group had weekly clinic visits until stabilization of their diabetes
treatment program followed by at least monthly clinic visits for medical and
psychological supervision. Intensive treatment also involved daily telephone contact for
self-management review and adjustment during the first week of the trial followed by
monthly telephone calls. Staff was also available at each clinic for patients in the
intensive treatment group to contact via telephone 24 hours a day. The aim of the
intensive treatment group was to achieve and maintain normal or as close to normal
glycemic control, or below 6.5% (DCCT Research Group, 1986).
Participants attended study clinics quarterly. A1c was measured at quarterly visits,
retinopathy severity was measured at 6 month intervals, and both nephropathy and
depressive symptomatology were measured annually. Neuropathy was measured through
a standardized neurologic history and physical examination by neurologists at baseline, 5
years, and at the close out of the study.
Statistical Analysis
Four models were be tested for this study for the full sample and the primary, as
well as for secondary intervention cohorts separately. First, three simple-mediation
models were tested evaluating the meditational role of A1c in the relationship between
DCCT treatment group assignment (intensive or standard treatment) and the presence and
severity of microvascular diabetes related complications (see Figure 1). Each diabetes
complication (i.e., retinopathy, nephropathy, and neuropathy) was tested independently as
an outcome in the simple-mediation model. The models were tested longitudinally, with
A1c measurement points preceding each diabetes complication measurement point.
Level of glycemic control, as measured by A1c, was be averaged over the 4th and 12th
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quarterly visit (between years 1 and 3 of study participation) of the DCCT to capture the
early change in glycemic control expected to be achieved by intensive insulin treatment.
Average levels of microvascular diabetes complications between the 16th and 21st
quarterly visit (between years 4 and 5.25 of study participation) were analyzed in each
model. This time range captures the greatest variability in the data because diabetes
complications tend to occur increasingly with disease duration. DCCT inclusion
requirements precluded people with advanced retinopathy from participating in the study.
Therefore, many complications will not occur until later years in the study. Additionally,
neurologic history and physical examination for neuropathy was measured at baseline, 5
years, and study end only, so it is important to have a range that captures this data.
A multiple-mediator model was used to examine the relationship between A1c,
microvascular diabetes complications, and depressive symptomatology (see Figure 2) to
provide further evidence of the nature of this relationship over time within the
depression-as-consequence-model framework. Within the longitudinal model, measures
of A1c preceded measures of diabetes complications, and measures of complications
preceded depressive symptomatology measures. Measurement points for A1c and
microvascular complications for the multiple-mediator model were averaged over the
same time points as the simple mediator models previously stated. Depressive
symptomatology, as indicated by total scores on the depression subscale of the SCL-90-R,
was averaged between the 23rd and 28th quarterly visit (about 6 years into the study) to
capture the most data for participants who’s depressive symptom levels were not
measured exactly on the 24th quarterly visit.
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The models were tested using the mediation bootstrapping Sobel extension
method as described by Preacher and Hayes (2004 & 2008). Bootstrapping is a
nonparametric statistical approach that is the most powerful method of obtaining
confidence limits for specific indirect effects of mediation without assumptions of
sampling distribution. The multiple resampling bootstrapping methods of the analyses of
mediator models do not assume normality of the sampling distribution of the indirect
effect of the independent variable (IV) on the dependent variable (DV) that other
methods, such as the product-of-coefficients strategy, assume (Preacher & Hayes, 2004,
2008).
Simple mediation models were used to test the relationship between group
assignment (IV), A1c (mediator) and diabetes complications (DV; Preacher & Hayes,
2004). A multiple-mediator model was used to test the meditational impact of the
microvascular diabetic complications, retinopathy, neuropathy, and nephropathy
(mediators) on the relationship between A1c (IV) and depressive symptomatology (DV).
Testing multiple mediator models provides specific indirect effects of the ability of a
given mediator to uniquely mediate the effect of the IV on a DV controlling for all other
mediators in addition to total indirect effects. Relevant variables including gender, age,
baseline depressive symptomatology, baseline A1c level, baseline diabetes complications
severity (i.e., level of retinopathy, baseline albumin excretion, and neuropathy ratings),
duration of diabetes, and smoking status were controlled for in each of the four mediation
models tested. Baseline retinopathy levels were not controlled for the primary
intervention cohort because inclusion requirements precluded the presence of retinopathy
in this group.
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The simple mediation models answers the four hypotheses regarding the
relationship between DCCT group assignment, A1c, and diabetes related complications
for each diabetes related microvascular complication by providing the direct effects of
group assignment on the incidence and severity of each complication (hypothesis 1),
direct effects of group assignment on A1c (hypothesis 2), direct effects of A1c on the
incidence and severity of microvascular complications (hypothesis 3), and the indirect
effects of group assignment on the incidence and severity of each microvascular
complication with A1 as a mediator of that relationship (hypothesis 4). The multiple
mediator model answers all four hypotheses regarding the relationship between A1c,
microvascular complications, and depressive symptomatology by providing direct effects
of A1c on depressive symptomatology (hypothesis 1), direct effects of A1c on diabetes
complications (hypothesis 2), direct effects of diabetes complications on depressive
symptomatology (hypothesis 3), and specific and total indirect effects of A1c on
depressive symptomatology with diabetes complications as mediators of that relationship
(hypothesis 4).
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Table 1
Participant Baseline Descriptive Characteristics and Demographic Information
Full
Sample

Primary
Cohort

Secondary
Cohort

(N = 1441)

(n = 726)

(n = 715)

M (SD)

M (SD)

M (SD)

Agea

27.09 (7.11)

26.67 (7.41)

27.51 (6.78)

Educationa

14.09 (2.28)

13.92 (2.43)

14.26 (2.11)

Diabetes durationb

69.78 (49.67)

33.46 (16.39)

106.65 (44.72)

A1c

8.89 (1.59)

8.82 (1.67)

8.97 (1.50)

Retinopathy

2.18 (1.57

1 (0.00)

3.38 (1.44)

15.93 (18.76)

11.82 (8.29)

20.10 (24.60)

Neuropathy

2.59 (.65)

2.70 (.56)

2.48 (.72)

Depression

5.32 (5.05)

5.54 (5.27)

5.10 (4.81)

N (%)

N (%)

N (%)

Male gender

761 (52.8)

378 (52.1)

383 (53.6)

Married

706 (49.0)

351 (48.3)

355 (49.7)

White race

1391 (96.5)

698 (96.1)

693 (96.9)

Current smoker

304 (21.1)

145 (20.0)

159 (22.2)

Intensive treatment group
711 (49.3)
a
b
Note. = in years. = in months.

348 (47.9)

363 (50.8)

Characteristic

Albumin Excretion Rate
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Table 2
Diabetes Control and Complications Trial Neurologic End Point Definitions
Category

Definition

Confirmed clinical
neuropathy

A finding of definite clinical neuropathy by physical
examination and history confirmed by unequivocal
abnormality of either nerve conduction or autonomic
nervous system response as defined below

Clinical neuropathy

A definite diagnosis of peripheral diabetic neuropathy by
clinical examination based on the presence of at least two
of the following:
Physical symptoms
Abnormalities on sensory examination
Absent or decreased deep-tendon reflexes

Abnormal nerve
conduction

At least one abnormal conduction attribute on each of at
least two anatomically distinct peripheral nerves according
to the following standards:
Median motor nerve: Amplitude < 4.2 mV; Conduction
velocity < 49.0 m/sec; F-wave latency > 31.8 m/sec
Median sensory nerve: Amplitude < 10.0 µV; Conduction
velocity < 48.0 m/sec;
Peroneal nerve: Amplitude < 2.5 mV; Conduction velocity
< 40.0 m/sec; F-wave latency > 56.0 m/sec
Sural nerve: Amplitude <5.0 µV; Conduction velocity <
40.0 m/sec

Abnormal autonomic
response

Any of the following indications of cardiac autonomic
neuropathy:
R-R variation (mean resultant) < 15.0
R-R variation < 20.0 in combination with Valsalva ratio <
1.5
Orthostatic hypotension caused by autonomic neuropathy
as indicated by a decrease of at least 10 mm Hg in
diastolic blood pressure in postural studies confirmed by
blunted norepinephrine response in plasma catecholamine
specimens

Subclinical neuropathy

Abnormal nerve conduction, autonomic nervous system
response, or both without a definite diagnosis of peripheral
neuropathy by clinical examination
Note. From: DCCT Research Group (1995a). The effect of intensive diabetes therapy on
the development and progression of neuropathy. Annals of Internal Medicine, 122, 561568.
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Table 3
Abbreviated Summary of the Final Version of the Early Treatment Diabetic Retinopathy
Study Scale of Diabetic Retinopathy Severity for Individual Eyes
Scale Level

Severity

Definition

1

10

No retinopathy

Diabetic retinopathy absent

2

20

Very mild NPDR

Microaneurysms only

3

35

Mild NPDR

Microaneurysms plus hard exudates, cotton-wool
spots, and/or mild retinal hemorrhages

4

43

Moderate NPDR

Microaneurysms plus mild IRMA or moderate
retinal hemorrhages

5

47

Moderate NPDR

More extensive IRMA, severe retinal
hemorrhages, or venous beading in one quadrant
only

6

53

Severe NPDR

Severe retinal hemorrhages in four quadrants, or
venous beading in at least two quadrants, or
moderately severe IRMA in at least one quadrant

7

61

Mild PDR

NVE <0.5 disc area in one or more quadrants

8

65

Moderate PDR

NVE ≥0.5 disc area in one or more quadrants or
NVD <0.25-0.33 disc area

9

71-75

High-risk PDR

NVD≥0.25-0.33 disc area and/or vitreous
hemorrhage

10
81-85 Advanced PDR
Fundus partially obscured
Note. NPDR = nonproliferative diabetic retinopathy; IRMA = intraretinal microvascular
abnormalities; PDR = proliferative diabetic retinopathy; NVE = new vessels elsewhere;
NVD = new vessels on or within 1 disc diameter of optic disc.
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Table 4
Abbreviated Final Version of the Early Treatment Diabetic Retinopathy Study Scale of
Diabetic Retinopathy Severity for Persons
Step

Level (Worse Eye/Better Eye)

1

10/10

2

20/<20

3

20/20

4

35/<35

5

35/35

6

43/<43

7

43/43

8

47/<47

9

47/47

10

53/<53

11

53/53

12-23

≥61/<61
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Table 5
Diabetes Control and Complications Trial Scale of Nephropathy
Level

Description

1

AER < 40mg/24hrs

1a

AER < 15 mg/24hrs

1b

15 ≤ AER < 40 mg/24rs

2

40 ≤ AER < 100 mg/24hrs

3

100 ≤ AER < 200 mg/24hrs

4

200 ≤ AER < 300 mg/24hrs

5

AER ≥ 300 mg/24hrs and Creatinine Clearance ≥ 70 ml/min/1.73m2

6

AER ≥ 300 mg/24hrs and Creatinine Clearance < 70 ml/min/1.73m2

Note. AER = Albumin excretion rate.
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Direct Effects
Microvascular Complications

Intervention Condition
Intensive Insulin Treatment
vs. Standard Care

1. Retinopathy
2. Nephropathy
3. Neuropathy

c

Indirect Effects

A1c

a

b

Microvascular Complications

Intervention Condition
Intensive Insulin Treatment
vs. Standard Care

c’

1. Retinopathy
2. Nephropathy
3. Neuropathy

Figure 1. Graphical representation of the hypothesized simple-mediator model of DCCT
intervention treatment condition, A1c, and microvascular diabetes complications. Three
individual models with each microvascular complication as the dependent variable will
be tested.
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Direct Effects

A1c

Depressive Symptoms
c

Indirect Effects

s
Retinopathy
b1
a1
a2

Nephropathy

b2

A1c

Depressive Symptoms

c’
a3

Neuropathy

b3

Figure 2. Graphical representation of the hypothesized multiple-mediator model of A1c,
microvascular diabetes complications, and depressive symptomatology.
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Results
Descriptives, t-tests, and Correlational Analyses
Mean values and standard deviations for average A1c between quarterly visits 4
through 12, average retinopathy, nephropathy, and neuropathy levels between quarterly
visits 16 through 21, and average depressive symptomatology levels between quarterly
visit 23 and 28 are presented in Table 6. Values are presented for the full DCCT sample
and the primary and secondary intervention cohorts separately. Group comparisons
showed that participants in the primary intervention group had lower levels of
retinopathy, nephropathy, and neuropathy than participants in the secondary intervention
cohort (t(952.61) = -21.98, p < .001, d = .51, t(891.05) = -7.02, p < .001, d = .37,
t(1220.56) = 4.57, p < .001, d = .27, respectively), as expected. Average A1c levels were
higher in the primary intervention cohort than the secondary intervention cohort
(t(1432.52) = 2.07, p < .05, d = .11) and there was no difference in average depression
levels between the primary and secondary intervention cohorts (t(807) = 1.65, n.s., d =
.12).
Additionally, Pearson product-moment correlations between A1c, microvascular
complications, and depressive symptomatolgoy and point-biserial correlations between
these variables and DCCT treatment group assignment (standard vs. intensive treatment)
are presented in table 6 for the full sample, primary intervention cohort, and secondary
intervention cohort. As expected, A1c was significantly related to DCCT treatment group
assignment and all microvascular complications in the expected direction in the full
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sample as well as in both the primary and secondary intervention cohorts. Additionally,
the microvascular complications were all significantly correlated in all samples. A1c was
significantly related to depression in the full sample and the secondary intervention
cohort, but not in the primary intervention cohort. DCCT treatment group assignment was
significantly related to all variables except depression in the full sample and primary
intervention group. Treatment group assignment and depression were significantly related
in the secondary intervention group, however. Depressive symptomatology level was
significantly related to neuropathy in the full sample and retinopathy and neuropathy in
the secondary intervention cohort, but was not significantly correlated to any
microvascular complications in the primary intervention cohort.
Single Mediation Models Analyses
Three proposed simple mediation models, illustrated in Figure 1, included A1c as
a mediating variable in the relationship between DCCT treatment group assignment and
retinopathy, nephropathy, and neuropathy. These three mediation models were tested for
the full DCCT sample as well as for the primary and secondary intervention cohorts
separately, resulting in a total of nine models. Age, gender, duration of diabetes, smoking
status, and baseline values of A1c, depressive symptomatology, and microvascular
complications were entered as covariates to control for their possible effects in each
model. Retinopathy was omitted as a covariate for the primary intervention cohort model.
It was predicted that DCCT treatment group assignment would be related to the presence
and severity of each microvascular complication and that A1c would mediate these
relationships.
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To test for the significance of the mediation effect the Preacher and Hayes (2008)
method of calculating standard errors and confidence intervals was used with 5,000
bootstrap samples used to estimate the bias corrected and accelerated confidence
intervals. Results of these analyses can are summarized in Table 7. The total effect of
DCCT intervention group on the severity of microvascular complications was significant
for all three complications in the full sample as well as in the primary and secondary
intervention cohorts. Indirect effects were significant for all of the models tested except
for the model testing the meditational role of A1c on the relationship between DCCT
treatment group and nephropathy in the primary intervention cohort. With inclusion of
A1c as a mediating variable, the direct effect of DCCT group assignment on
microvascular complications was nonsignificant for all models tested. This suggests that,
with one exception of nephropathy in the primary intervention cohort, there is a
significant mediation effect of DCCT treatment group assignment on microvascular
complications through A1c, and A1c fully mediates the relationship between DCCT
group assignment and microvascular complications. The full models, including DCCT
treatment group assignment, A1c, and all covariates, accounted for a significant
proportion of the variance (p < .001) in microvascular complication levels for all models
tested. These results provide evidence for the assumption that the differences in the
severity of microvascular complications seen in the DCCT are in fact due to differences
in A1c resulting from the differences in treatment.
Multiple Mediation Models Analyses
A proposed multiple mediation model, illustrated in Figure 2, included
retinopathy, nephropathy, and neuropathy as mediating variables in the relationship
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between A1c and level of depressive symptomatology. The multiple mediator model was
tested for the full DCCT sample as well as for the primary and secondary intervention
cohorts separately, resulting in a total of three multiple mediator models. Age, gender,
duration of diabetes, smoking status, and baseline values of A1c, depressive
symptomatology, and microvascular complications were entered as covariates to control
for their possible effects in each model. Because participants in the primary intervention
cohort had no baseline retinopathy, retinopathy was omitted as a covariate for the primary
intervention cohort model. It was predicted that A1c would be positively related to
depressive symptomatology and that the severity of microvascular complications would
mediate this relationship. Multiple mediator models in which all of the microvascular
complications were entered simultaneously allowed for investigation of the total indirect
effect of microvascular complications on the relationship between A1c and depressive
symptomatology as well as the specific indirect effects of each of the individual
complications while controlling for the other complications.
Results of the tests of multiple mediators for the full DCCT sample, the primary
intervention cohort, and the secondary intervention cohort can be found in Figure 3,
Figure 4, and Figure 5, respectively. In both the full DCCT sample and the secondary
intervention cohort, total effects (c) indicated significant and substantial relations
between A1c and depressive symptomatology levels. However, the total effect of the
relationship between A1c and depressive symptomatology was not significant in the
primary prevention cohort.
To test for the significance of the mediation effect the Preacher and Hayes (2008)
method was used with 5,000 bootstrap samples used to estimate the bias corrected and
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accelerated confidence intervals. Significance tests of the mediation effects can be found
in Table 8. Total indirect effects were significant for the full DCCT sample as well as for
the secondary intervention cohort. For the full DCCT sample, both nephropathy and
neuropathy had significant (p < .05) specific indirect effects on the relationship between
A1c and depressive symptomatology. None of the specific indirect effects, however, were
significant for the primary intervention or secondary intervention cohorts. Contrasts of
specific indirect effects were examined and all pairwise contrasts of indirect effects were
nonsignificant, indicating that the magnitude of the specific indirect effects of the
different microvascular complications could not be distinguished from one another in any
of the models tested.
Despite significant mediation, the direct effects (c’) remained significant in both
the full DCCT sample and the secondary intervention cohort, although the strength of the
relationship was attenuated, suggesting that the presence and severity of microvascular
complications partially mediates the relationship between A1c and depressive
symptomatology in these samples. Total effects, mediation effects, and direct effects
were all nonsignificant in the primary intervention cohort. The full models, including
A1c, the three microvascular complications, and all covariates, accounted for a
significant proportion of the variance (p < .001) in depressive symptomatology levels for
all models tested. The models explained 18, 14, and 22 percent of the variance in
depressive symptomatology levels for the full sample, primary intervention cohort, and
secondary intervention cohort, respectively.
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Table 6
Descriptive Statistics and Correlations of Average A1c, Retinopathy, Nephropathy,
Neuropathy, and Depressive Symptomatology Levels.
Sample
Fulla

Primaryb

Secondaryc

1

2

3

4

5

M

SD

N

8.17

1.57

1440

3.25

2.39

1359

1.17

.61

1419

2.42

.76

1240

1. A1c average

––

2. Retinopathy

.24**

––

3. Nephropathy

.18**

.35**

––

4. Neuropathy

-.16**

-.21**

-.15**

––

5. Depression

.11**

.06

-.12**

––

5.17

6.10

809

6. DCCT Group

-.62**

-.09**

.13**

-.06

––

––

1441

1. A1c average

––

8.25

1.63

726

2. Retinopathy

.45**

––

2.01

1.11

657

3. Nephropathy

.16**

.18**

––

1.06

.30

716

4. Neuropathy

-.17**

-.13**

-.09*

––

2.53

.71

554

5. Depression

-.02

-.05

.03

-.11

––

5.62

6.22

310

6. DCCT Group

-.65**

-.24**

.15**

.03

––

––

726

1. A1c average

––

8.08

1.50

714

2. Retinopathy

.31**

––

4.41

2.66

702

3. Nephropathy

.23**

.32**

––

1.28

.79

703

4. Neuropathy

-.18**

-.20**

-.16**

––

2.33

.79

686

5. Depression

.19**

.10*

.08

-.15**

––

4.89

6.02

499

6. DCCT Group

-.58**

-.20**

-.11**

.13**

-.11*

––

––

715

.03
-.16**

-.09*

Note. * p < .01. ** p < .001. Average A1c values calculated between quarterly visits
(QV) 4-12.
Average retinopathy, nephropathy, and neuropathy values calculated between QV 16-21.
Average depressive symptomatology levels between QV 23-28.
a
= ns for correlations range from 777 – 1419. b = ns for correlations range from 297 –
716. c = ns for correlations range from 480 – 704.
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-1.78***
-1.79***
-1.79***

Secondary Retinopathyg

Nephropathyh

Neuropathyi

-.10***

.10***

.45***

-.07*

.01

.20***

-.09***

.05***

.33***

on DV (b)

Effect of M

.21***

-.17**

-.92***

.21***

-.06**

-.52***

.21***

-.11***

-.73***

Effect (c)

Total

.18* (.05)

-.18* (.06)

-.80* (.16)

.15* (.06)

-.03 (.02)

-.42* (.10)

.16* (.04)

-.11* (.03)

-.63* (.10)

(ab) (SE)

[.08, .28]

[-.32, -.08]

[-1.14, -.50]

[.03, .27]

[-.07, .003]

[-.62, -.25]

[.09, .24]

[-.18, -.05]

[-.83, -.44]

95% CI

Indirect Effect

Note. * p < .05. ** p < .01. *** p < .001. All coefficients represent point estimates while
controlling for gender, age, diabetes duration, smoking status, and baseline values of A1c,
depressive symptomatology, and microvascular complications.
a
n = 1347. b n = 1407. c n = 1232. d n = 652. e n = 711. f n = 552. g n = 695. h n = 696. i n = 680.

-2.07***

Neuropathyf

-1.92***

Neuropathyc

-2.11***

-1.95***

Nephropathyb

Nephropathye

-1.93***

Retinopathya

-2.07***

on M (a)

Variable (DV)

Retinopathyd

Primary

Full

Effect of IV

Dependent

for the full DCCT Group, and the Primary and Secondary Intervention Cohorts.

Mediation of the Effect of DCCT Treatment Group on Microvascular Complications through A1c

Table 7

.03

.01

-.12

.06

-.03

-.10

.05

-.0004

-.10

(c’)

Direct Effect

.22***

.24***

.49***

.15***

.09***

.33***

.20***

.21***

.58***

R2

43
.05* (.03)
.08* (.04)

Nephropathy

Neuropathy

[.01, .18]

[.0001, .12]

[-.02, .17]

.08 (.07)

.01 (.03)

-.06 (.07)

.03 (.10)

Coefficient (SE)

Indirect Effects

[-.02, .27]

[-.03,.13]

[-.23, .05]

[-.15, .27]

95% CI

Bootstrapping

Primary Prevention Cohortb

a

n = 766, bn = 295, cn = 471.

and microvascular complications.

age, diabetes duration, smoking status, and baseline values of A1c, depressive symptomatology,

confidence interval (CI). All coefficients represent point estimates while controlling for gender,

Note. *p < .05 as determined by the 95% bias corrected and accelerated bootstrapping

.06 (.05)

[.06, .34]

95% CI

Coefficient (SE)
.19* (.07)

Bootstrapping

Indirect Effects

Full DCCT Cohorta

Retinopathy

Total mediated effect

Mediators

primary prevention cohort, and secondary intervention cohort.

complications of retinopathy, nephropathy, and neuropathy in the full DCCT participant cohort,

Mediation of the effect of A1c on depressive symptomatology through the microvascular

Table 8

.06 (.05)

.05 (.05)

.11 (.07)

.22* (.09)

Coefficient (SE)

Indirect Effects

[-.02, .18]

[-.02, .16]

[-.01, .27]

[.06, .43]

95% CI

Bootstrapping

Secondary Intervention Cohortc

Direct Effects

A1c

B = .52*** (.14)

Depressive Symptoms

Indirect Effects

Retinopathy

Nephropathy

A1c

B = .33* (.15)

Depressive
Symptoms
R2 =.18***

Neuropathy

Figure 3. Multiple mediation test of the role of microvascular complications in the
relationship between A1c and depressive symptomatology for the full DCCT sample. All
coefficients represent unstandardized regression coefficients (Standard Error) while
controlling for age, gender, diabetes duration, smoking status, and baseline levels of A1c,
depression, and microvascular complications.
44

Direct Effects

A1c

B = .25 (.24)

Depressive Symptoms

Indirect Effects

Retinopathy

Nephropathy

A1c

B = .21 (.26)

Depressive
Symptoms
R2 =.14***

Neuropathy

Figure 4. Multiple mediation test of the role of microvascular complications in the
relationship between A1c and depressive symptomatology for the primary prevention
cohort of the DCCT. All coefficients represent unstandardized regression coefficients
(standard error) while controlling for age, gender, diabetes duration, smoking status, and
baseline levels of A1c, depression, and microvascular complications.
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Direct Effects

A1c

B = .68*** (.18)

Depressive Symptoms

Indirect Effects

Retinopathy

Nephropathy
Depressive
Symptoms
R2 =.22***

A1c

B = .47* (.19)

Neuropathy

Figure 5. Multiple mediation test of the role of microvascular complications in the
relationship between A1c and depressive symptomatology for the secondary intervention
cohort of the DCCT. All coefficients represent unstandardized regression coefficients
(standard error) while controlling for age, gender, diabetes duration, smoking status, and
baseline levels of A1c, depression, and microvascular complications.
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Discussion
The Relationship Between A1c, Complications, and Depressive Symptoms
The current study examined the relationship between A1c, microvascular
complications, and depressive symptomatology in people with type 1 diabetes. The
DCCT data set was used to examine these relationships because it provides longitudinal
data which enhances our understanding of the temporal sequence involved in these
relationships. Results from preliminary analyses were consistent with hypotheses, as A1c
fully explained the relationship between DCCT treatment group and the severity of three
microvascular complications: retinopathy, neuropathy, and nephropathy. The primary
goal of the study was to determine if the severity of these microvascular complications
explained the relationship between A1c and depressive symptoms. Consistent with
hypotheses, the severity of microvascular complications helps to explain the relationship
between A1c and depressive symptoms. The severity of microvascular complications
partially mediated the relationship between A1c and depressive symptoms for the full
sample as well as for a secondary intervention subset of participants who began the study
with early stage levels of retinopathy. However, in the primary prevention cohort whose
members had no baseline retinopathy, A1c was not predictive of depressive
symptomatology levels, and microvascular complications did not mediate the relationship
between A1c and depressive symptoms. For the full sample, the A1c-depressive
symptoms relationship was explained in part by the combined effect of all three
microvascular complications. However, further analyses indicated that the combined
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effect was primarily due to specific indirect effects of nephropathy and neuropathy (but
not retinopathy). Additionally, in the secondary intervention cohort, the A1c-depressive
symptoms relationship was explained in part by the combined effect of all three
microvascular complications, but not by specific effects of the individual microvascular
complications. These results provide support for diabetic complications as one
explanation of the relationship between A1c and depressive symptoms, specifically in
later stages of the diabetes disease process when microvascular complications become
more severe.
The results of the present study suggest that microvascular complications of
diabetes significantly contribute to depressive symptom levels and explain the
relationship between A1c, both a measure of glycemic levels over time as well as an
index of success in the self-management of diabetes, and depression levels. These
findings are consistent with a consequence model of diabetes and depression, which
suggests that depressive symptoms result as a consequence of medical problems that
occur as a result of poor glycemic control (W. P. Sacco, et al., 2007; W. P. Sacco, et al.,
2005). The antecedent theory of depression in diabetes, which suggests that medical
problems arise as a result of depression leading to decreased self-management and
increased A1c, may be a reasonable alternative or even a complement to the consequent
model; i.e., a bidirectional model is plausible. However, the longitudinal nature of the
current models tested provides evidence for the hypothesized temporal relationship
between A1c, diabetes related complications, and depressive symptom levels. This
temporal evidence lends further support for the consequence model of the development of
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depression in people with diabetes and its relation to A1c and associated medical
problems.
Additionally, the results suggest that the explanatory role of microvascular
complications in the relationship between A1c and depression tends to be most evident
for people with more severe diabetic complications. Results for the full sample were
driven by the secondary cohort, which was comprised of people with significantly higher
baseline levels of retinopathy, longer diabetes disease duration, and, therefore, longer
exposure to hyperglycemia than their primary cohort counterparts. The difference in the
role of microvascular complications in the relationship between A1c and depressive
symptoms for the cohorts may be reflective of these differences. Microvascular
complications tend to develop and progress with longer disease duration (Fong, et al.,
2004; Luk, et al., 2008; Moss, Klein, & Klein, 1992; Orchard, et al., 1990), and are often
asymptomatic at early stages (Boulton, et al., 2005; Fong, et al., 2004; Soldo, Brkljacic,
Bozikov, Drinkovic, & Hauser, 1997). Based on these trends, the detrimental effects of
microvascular complications on psychological health are perhaps not evident until the
complications are sufficiently severe enough to be symptomatic. The symptoms of these
diabetes complications may be disruptive through pain and functional impairment (W. P.
Sacco, Bykowski, & Mayhew, 2010) that result with increasing severity of the
complications, consequentially resulting in higher depressive symptom levels.
Strengths
These results are consistent with previous studies which have shown positive
associations between A1c, depression, and microvascular complications (de Groot,
Anderson, Freedland, Clouse, & Lustman, 2001; Lustman, et al., 2000). Similarly, results
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are consistent with the few previous longitudinal studies of A1c and depressive
symptoms available. Longitudinal analysis of A1c and depressive symptoms in people
with type 2 diabetes suggest that poor glycemic control can increase risk of depressive
symptoms for people with intensive (i.e., insulin) treatment regimen, but not those on oral
medication alone (Aikens, Perkins, Lipton, & Piette, 2009). An additional longitudinal
investigation shows a positive relationship between A1c and depression over time, but
the nature of the data precludes causal inferences (Richardson, Egede, Mueller, Echols, &
Gebregziabher, 2008). However, most studies use cross-sectional data which severely
limits the conclusions that can be drawn from the results. Furthermore, no previous
studies have examined the interrelationship among these variables in a single model using
longitudinal experimental data, as the current study does, which provides evidence of a
temporal relationship between the variables. The present study also adds to the existing
body of research by providing a comprehensive theoretically based model of the
relationship between these variables over time providing evidence for the depression as
consequence model of diabetes. Additionally, the present study has the advantage of
using objective biological markers in the measurement of the microvascular
complications, including nerve conduction studies for neuropathy and albumin excretion
rates for nephropathy, thus providing more concrete and accurate measurements of the
symptom severity without relying on potentially inaccurate subjective self-reports or
global clinical judgments.
Additionally, a multiple mediator model with bootstrapping was used to
investigate the role of microvascular complications in the relationship between glycemic
control and depressive symptomatology. This is a superior method of analysis than single
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mediator models because it provides information of the total mediation effect of the
microvascular complications, accounting for their intercorrelation, as well as specific
indirect effects of each individual complication while controlling for the others. The
analyses also statistically controlled for factors that are known to be associated with
microvascular complications and depressive symptomatology. By controlling for baseline
levels of variables included in the model as well as possible demographic confounds, the
effects of A1c on depression and the meditational role of complications in this
relationship could be identified independent of the known potential confounds.
Clinical Implications
The role of A1c and microvascular complications in the development of
depressive symptomatology is an important factor to consider for clinical interventions.
Because the relationship between A1c, microvascular complications, and depression may
not be evident until later in the diabetes disease process, prevention of later psychological
issues related to the disease should be focused on through an emphasis on effective
disease management early on in the disease process. Diabetes self-management programs
are considered a critical element of care for people with diabetes, as they have been found
to be effective in improving glycemic control (Ellis, et al., 2004; Funnell, et al., 2009;
Norris, Lau, Smith, Schmid, & Engelgau, 2002). Addressing related psychosocial issues
is recommended as core components of self-management curriculum in addition to
diabetes-specific behavioral and medical considerations (Funnell, et al., 2009). In light of
the current findings it is recommended that diabetes self-management interventionists be
especially vigilant about the psychological effects, particularly depression, of medical
complications associated with diabetes. Consideration of these associations should be
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given not only for the psychological health of people with diabetes, but also because the
relationship between diabetes and depression may very well be bidirectional, and
depression is likely to interfere with adherence to diabetes self-management regimens
(Gonzalez, et al., 2008).
Limitations
Some caveats should be noted. First, the current study was based on a long-term
clinical research trial with a well-educated largely white sample of people with type 1
diabetes. It is possible that clinical trials, which generally require participants follow
fairly strict protocol regulations, attract a unique group of participants with characteristics
that differ in significant ways from the general population. Furthermore, the homogeneity
of race and educational levels in the current sample limits the applicability of the findings
to the larger population. It is also possible that the relationships gleaned in the current
study of people with type 1 diabetes may manifest somewhat differently in people with
type 2 diabetes. Given that the overwhelming majority of cases of diabetes are type 2, it
would be useful to test the applicability of the current models in a type 2 diabetes
population. Furthermore, differences in sample size between the primary and secondary
intervention cohorts may contribute to differences in power and, therefore, the ability to
detect significant relationships between the variables in the mediation models. Further
testing of these models in comparably sized samples of people with diabetes with varying
stages of the disease and varying severities of complications should be tested.
Additionally, despite using longitudinal experimental data, testing for mechanisms of the
proposed relationship between A1c and depressive symptoms, and controlling for known
variables that can influence the variables investigated, the possibility of a third
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unmeasured variable accounting for the present relationships remains. Potential
confounding variables such as self-management and adherence among others should be
considered in future investigations.
Future Directions
Continued exploration of the applicability of the current findings in a more
heterogeneous sample including greater variability in educational attainment levels and
racial and ethnic backgrounds in a longitudinal fashion would be prudent. Additionally,
the models of the interrelationships between the A1c, microvascular complications, and
depressive symptoms should be investigated in people with type 2 diabetes. Furthermore,
future studies should investigate the mechanisms through which microvascular
complications contribute to depressive symptomatology levels, such as by contributing to
loss of reinforcement through pain and functional limitation.
Conclusion
In summary, A1c mediated the relationship between DCCT group assignment and
the severity of the diabetes related microvascular complications of retinopathy,
nephropathy, and neuropathy. Furthermore, A1c was related to depressive symptom
levels in the full sample and the secondary cohort, and this relationship was explained, in
part, by the severity of microvascular complications. Longitudinal analyses provide
evidence for the temporal relationship between these variables. These results are
consistent with the depression-as-consequence-model of depression, which proposes that
depression occurs as a result of medical symptoms and complications that occur from
poor diabetes self-management and poorly controlled glycemic levels. However, these
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relationships may not be evident until later in the disease process when complications
become increasingly severe and problematic.
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Symptom Checklist-90-Revised Depression Dimension Subscale
Instructions: Below is a list of problems people sometimes have. Please read each one
carefully, and blacken the circle that best describes HOW MUCH THAT PROBLEM
HAS DISTRESSED OR BOTHERED YOU DURING THE PAST 7 DAYS
INCLUDING TODAY. Blacken the circle for only one number for each problem and do
not skip any items. If you change your mind erase your first mark carefully.
“Number” refers to the following descriptor phrases:
0 = Not at all; 1 = A Little bit; 2 = Moderately; 3 = Quite a Bit; 4 = Extremely
Item

0

1

2

3

4

5. Loss of sexual interest or pleasure

○

○

○

○

○

14. Feeling low in energy or slowed down

○

○

○

○

○

15. Thoughts of ending your life

○

○

○

○

○

20. Crying easily

○

○

○

○

○

22. Feelings of being trapped or caught

○

○

○

○

○

26. Blaming yourself for things

○

○

○

○

○

29. Feeling lonely

○

○

○

○

○

30. Feeling blue

○

○

○

○

○

31. Worrying too much about things

○

○

○

○

○

32. Feeling no interest in things

○

○

○

○

○

54. Feeling hopeless about the future

○

○

○

○

○

71. Feeling everything is an effort

○

○

○

○

○

79. Feelings of worthlessness

○

○

○

○

○
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Neuropathy Measurement Definition
Nerve conduction of the dominant median (motor and sensory), peroneal (motor),
and sural nerves was evaluated using standard techniques and stimulation-to-recording
electrode distances or specified anatomical landmarks. A standardized physical and
neurologic history was completed by DCCT neurologists at baseline, 5 years, and at
study end. Peripheral, somatic, and autonomic neuropathic symptoms were investigated
during the neurological examination. Deep-tendon reflexes and peripheral sensation
including light touch, pin-prick, temperature, and position, were measured during the
physical exam. Clinical neuropathy was indicated by abnormal findings in any two
categories of neuropathic symptoms, sensory deficits, or impaired reflexes. Confirmed
clinical neuropathy was defined as clinical neuropathy determined by a definite abnormal
neurologic examination (defined by at least two of the following: sensory signs, absent or
hypoactive reflexes consistent with distal symmetrical polyneuropathy, or positive
responses among symptoms) confirmed by abnormal testing in either nerve conduction or
autonomic nervous system testing or both (defined by a value above or below the
absolute threshold of normal for amplitude, velocity of conduction, distal latency, or Fwave latency in at least two anatomically distinct nerves). Possible clinical neuropathy
was defined as a participant with only one abnormal finding among symptoms sensory
signs, or absent or hypoactive reflexes, regardless of the normality of nerve conduction
study outcomes. Secondary outcome variables assessed included clinical neuropathy
(defined as a peripheral diabetic neuropathy diagnosis based on the presence of at least
two of the following: physical symptoms, abnormalities on sensory examination, and
decreased or absent deep-tendon reflexes), subclinical neuropathy (as defined by either
abnormal nerve conduction, abnormal autonomic nervous system response, or
abnormalities in both of these measurements without a definite diagnosis of peripheral
neuropathy by clinical examination), abnormal nerve conduction, and abnormal
autonomic nervous system test results (DCCT Research Group, 1995a).
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